| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(24S)-MC 976 targets the vitamin D receptor (VDR) pathway, consistent with its classification as a Vitamin D3 derivative and Calcipotriol analogue. VDR is a nuclear receptor that regulates gene transcription involved in calcium homeostasis, cell proliferation, and differentiation.
|
|---|---|
| ln Vitro |
In vitro activity data for (24S)-MC 976 are limited. As a Vitamin D3 derivative, it is expected to modulate VDR-mediated gene transcription and cellular differentiation. Related Vitamin D analogues exhibit antiproliferative effects on cancer cell lines and regulate keratinocyte differentiation.
|
| ln Vivo |
In vivo activity data for (24S)-MC 976 are not extensively characterized. As a Vitamin D3 analogue related to Calcipotriol, it may have applications in dermatological conditions such as psoriasis. Calcipotriol, the parent compound, is approved for the topical treatment of plaque psoriasis.
|
| Enzyme Assay |
In vitro receptor binding assays for (24S)-MC 976 would typically involve competition binding studies using VDR-containing nuclear extracts or recombinant VDR protein. Radiolabeled calcitriol or other VDR ligands are used as tracers, and binding affinity (IC50 or Ki) is determined by measuring displacement via scintillation counting or fluorescence polarization.
|
| Cell Assay |
Cellular assays for (24S)-MC 976 would be conducted using cell lines expressing VDR, such as keratinocytes or cancer cell lines. Cells are treated with the compound at various concentrations (1 nM to 10 uM) for 24-72 hours. VDR-mediated transcriptional activity is assessed by reporter gene assays. Cell proliferation and differentiation markers are measured by MTT assay and qPCR.
|
| Animal Protocol |
In vivo animal studies for (24S)-MC 976 are not well-established in the literature. As a Vitamin D3 analogue, it could potentially be evaluated in mouse models of psoriasis or other skin disorders, administered topically or via oral gavage. However, specific protocols and efficacy data have not been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (24S)-MC 976 have not been extensively characterized. The compound has a molecular weight of 414.62 and formula C27H42O3. It is a solid powder and is typically stored at -20degC. Solubility and bioavailability data are not available in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for (24S)-MC 976 are limited. As a research compound related to Vitamin D3, standard safety assessments would include evaluation of calcium homeostasis effects and hypercalcemia risk, which are known concerns for Vitamin D analogues. No significant toxicity has been reported in the available literature.
|
| References | |
| Additional Infomation |
(24S)-MC 976 is a research-use compound not approved for clinical therapeutic applications. It is a Vitamin D3 derivative and Calcipotriol analogue used in metabolic and dermatological research. The compound is for research use only and not for human therapeutic application.
|
| Molecular Formula |
C27H42O3
|
|---|---|
| Molecular Weight |
414.62058
|
| Exact Mass |
414.313
|
| CAS # |
112849-14-6
|
| Related CAS # |
MC 976;129831-99-8;(24R)-MC 976;112828-09-8
|
| PubChem CID |
71576665
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
5.314
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
703
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CC[C@@H](C1CC1)O)[C@H]2CC[C@@H]\3[C@@]2(CCC/C3=C\C=C/4\C[C@H](C[C@@H](C4=C)O)O)C
|
| InChi Key |
NQHWMFGCRBTMOO-DWCMLEBJSA-N
|
| InChi Code |
InChI=1S/C27H42O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h7,10,17,20,22-26,28-30H,2,4-6,8-9,11-16H2,1,3H3/b19-7+,21-10-/t17-,22-,23-,24+,25+,26+,27-/m1/s1
|
| Chemical Name |
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5S)-5-cyclopropyl-5-hydroxypentan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (3). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4118 mL | 12.0592 mL | 24.1185 mL | |
| 5 mM | 0.4824 mL | 2.4118 mL | 4.8237 mL | |
| 10 mM | 0.2412 mL | 1.2059 mL | 2.4118 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
